Considering targeted therapies in pre-clinical development, an enhanced cytotoxic effect has been observed in p53-mutant cancer cell cultures when PRIMA-1/APR-246 was combined to tunicamycin (ER stress inducer) in myeloma cells [54], or to wortmannin (PI3K inhibitor) in AML cells [53]. Here, TP53 is linked to cancer.